AC Immune (ACIU) Invested Capital (2016 - 2025)

AC Immune (ACIU) has 10 years of Invested Capital data on file, last reported at $18.4 million in Q4 2025.

• On a quarterly basis, Invested Capital fell 20.3% year-over-year to $18.4 million in Q4 2025; TTM through Mar 2026 was $18.4 million, a 20.3% decrease from a year earlier, with the FY2025 full-year figure at $17.7 million, down 23.17% from the prior year.
• Invested Capital for Q4 2025 stood at $18.4 million, down from $23.0 million in the prior quarter.
• Over the last five years, Invested Capital for ACIU reached as high as $23.5 million in Q4 2021 and fell as low as $13.6 million in Q4 2022.
• Historically, Invested Capital has averaged $19.4 million across 5 years, with a median of $18.4 million in 2025.
• Across the five-year window, Invested Capital jumped 37.01% in 2021 and slumped 41.87% in 2022, its largest moves.
• Year by year, Invested Capital stood at $23.5 million in 2021, then slumped by 41.87% to $13.6 million in 2022, then surged by 34.35% to $18.3 million in 2023, then grew by 25.66% to $23.0 million in 2024, then fell by 20.3% to $18.4 million in 2025.
• Per Business Quant data, the three most recent Invested Capital figures were $18.4 million in Q4 2025, $23.0 million in Q4 2024, and $18.3 million in Q4 2023.